Brainstorm Cell Therapeutics Announces Pricing Of $7.5M Registered Direct Offering For The Purchase And Sale Of 4,054,055 Shares Of Common Stock And Warrants At A Price Of $1.85/Share, Warrants Will Have An Excersize Price Of $2/Share
Portfolio Pulse from Happy Mohamed
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has announced a registered direct offering for the purchase and sale of 4,054,055 shares of common stock and warrants at a price of $1.85 per share. The warrants will have an exercise price of $2.00 per share and will expire five years from the date of issuance. The offering is expected to close on July 19, 2023, and is expected to generate approximately $7.5 million in gross proceeds.
July 17, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BrainStorm Cell Therapeutics' registered direct offering could potentially dilute existing shareholders' equity, but it will also provide the company with additional capital.
The offering could dilute the value of existing shares, which may negatively impact the stock price in the short term. However, the additional capital could be used to fund operations and growth, which could have a positive impact in the long term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100